Literature DB >> 20956161

Treatment of COPD: from pharmacological to instrumental therapies.

M Alifano1, A Cuvelier, A Delage, N Roche, B Lamia, L C Molano, L-J Couderc, C-H Marquette, P Devillier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20956161     DOI： 10.1183/09059180.00008009

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN： 0905-9180


× No keyword cloud information.
  6 in total

1.  Atorvastatin and Simvastatin Promoted Mouse Lung Repair After Cigarette Smoke-Induced Emphysema.

Authors:  Vanessa Pinho-Ribeiro; Adriana Correa Melo; Emanuel Kennedy-Feitosa; Adriane Graca-Reis; Marina Valente Barroso; Isabella Cattani-Cavalieri; Giovanna Marcella Cavalcante Carvalho; Walter Araújo Zin; Luis Cristóvão Porto; Lycia Brito Gitirana; Manuella Lanzetti; Samuel Santos Valença
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

2.  Suppressed expression of T-box transcription factors is involved in senescence in chronic obstructive pulmonary disease.

Authors:  George K Acquaah-Mensah; Deepti Malhotra; Madhulika Vulimiri; Jason E McDermott; Shyam Biswal
Journal:  PLoS Comput Biol       Date:  2012-07-19       Impact factor: 4.475

Review 3.  Pre-operative pulmonary assessment for patients with hip fracture.

Authors:  I-L Lo; C-W Siu; H-F Tse; T-W Lau; F Leung; M Wong
Journal:  Osteoporos Int       Date:  2010-11-06       Impact factor: 4.507

4.  Knowledge and practice of dry powder inhalation among patients with chronic obstructive pulmonary disease in a regional hospital, Nepal.

Authors:  Mira Adhikari Baral
Journal:  Int J Gen Med       Date:  2018-12-24

5.  Compliance of Pharmacotherapy with GOLD Guidelines: A Longitudinal Study in Patients with COPD.

Authors:  Fabian A Grewe; Noriane A Sievi; Matteo Bradicich; Maurice Roeder; Thomas Brack; Martin H Brutsche; Martin Frey; Sarosh Irani; Jörg D Leuppi; Robert Thurnheer; Christian F Clarenbach; Malcolm Kohler
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-03-26

6.  Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.

Authors:  Amparo Buenestado; Marie-Camille Chaumais; Stanislas Grassin-Delyle; Paul-André Risse; Emmanuel Naline; Elisabeth Longchampt; Hermann Tenor; Philippe Devillier
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.